Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Verastem Releases Results of Recent Study

Verastem, Inc., a drug company specializing in the development of medications to treat cancer by targeting and killing cancer stem cells, has just published a research paper titled “Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship.” The paper was published in the most recent edition of the journal Science Translational Medicine, and reveals a successful study of the use of FAK (focal adhesion kinase) inhibition.

The highly technical study involved discovering that when there is a loss of the tumor suppressor merlin, a phenomenon that happens in approximately half of all mesothelioma patients, there is an increase in responsiveness to drugs that target cancer stem cells that have been inhibited through focal adhesion kinase. The impact of the procedure was demonstrated both on a cellular level and in in vivo models. The study indicated how strong the tumor-initiating capability of mesothelioma cancer stem cells are and that the medications that are currently the first line of defense in the treatment of mesothelioma actually augment those stem cells. By contrast, FAK inhibition effectively reduces the growth of the stem cells.

According to Jonathan Pachter, Ph.D. and Verastem Head of Research, “These data demonstrate that FAK inhibition is particularly effective in models of merlin-negative mesothelioma. These results build upon key findings published earlier this year by our collaborators at Fox Chase Cancer Center which demonstrated that merlin loss drives the development of highly aggressive malignant mesothelioma which is enriched for cancer stem cells. Accordingly, in a merlin-negative mesothelioma patient-derived tumor model, FAK inhibitor treatment as maintenance therapy prolonged the inhibition of tumor growth following treatment with pemetrexed and cisplatin.”

The results of the study are the basis for Verastem’s current clinical trial that is treating patients with mesothelioma after they have been treated with pemetrexed (Alimta) and platinum. Mesothelioma is a particularly aggressive and rare form of cancer that impacts those who have been exposed to asbestos. Mesothelioma affects approximately 59,000 patients worldwide per year, and is diagnosed in roughly 3,000 patients in the United States. It is always considered fatal, and is particularly difficult to treat because it is generally so far advanced by the time that it begins to exhibit symptoms. The current treatments for mesothelioma include a variety of surgeries, as well as the use of radiation therapy and chemotherapy.

Terri Oppenheimer

Terri Oppenheimer is an experienced blog writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of expertise include health, medical research, and law.

Get Your FREE Resources Sent Overnight

  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –

Site Navigation

Where can I

Get Additional Help?

For over 15 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –

We are here to help you


If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

Quick Compensation - $30 Billion Trusts
$30 Billion Asbestos Trusts
Get Started